US FDA approves Vera's kidney disease drug

The FDA approved Vera Therapeutics' Trutakna, the first drug targeting BAFF and APRIL immune proteins for IgA nephropathy, a potentially fatal kidney disease, priced at $425,000 annually. The approval is based on phase 3 data showing 42% reduction in urinary protein versus placebo, entering a competitive market alongside Otsuka, Novartis, and Travere treatments.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.